Dr Lal PathLabs Ltd (DLPL IN): Volume Driven Topline Growth and Margin Improvement Continued in Q2
Dr Lal PathLabs reports 10% revenue growth in Q2, driven by volume, with bottomline surge outpacing revenue growth. The company has maintained 10%...
241 Views
Dr Lal PathLabs Ltd (DLPL IN): Poised for Next Level of Growth Amid Easing Price Competition
Dr Lal PathLabs expects 10% revenue growth fueled by patient volume in FY25. The company is looking for small or mid-sized acquisitions in South...
353 Views
Indonesia Strategy - Caught in a Perfect Updraft?
Despite the JCI knocking on all-time highs, valuations continue to look attractive with prospects of a better 2H2024 and lower interest rates. Top...
434 Views
Prodia (PRDA IJ) - Back to Core Testing
Prodia (PRDA IJ) FY2022 results saw declines in revenues and profits but from a COVID-high base and the numbers are now well-above 2019, with...
482 Views
Prodia (PRDA IJ) - A Standout in Diagnostics
Prodia (PRDA IJ) stands out in terms of its strong market positioning and track record together with attractive valuations, especially versus...
346 Views